Organiza:



HIGHLIGHTS AMERICAN TRANSPLANT CONGRESS ATC22023 JUNIO 3-7, 2023

En esta presentación puede haber mención a datos científicos que no están aprobados en el registro. Por favor, consulte la ficha técnica. Las opiniones expresadas en esta presentación corresponden únicamente a quienes las emiten y no representan necesariamente las opiniones de Chiesi España S.A.U.

Organiza:



HIGHLIGHTS AMERICAN TRANSPLANT CONGRESS ATTORNAL CONGRESS ATTORNAL CONGRESS ATTORNAL CONGRESS ATTORNAL CONGRESS

What's hot, what's new in Liver Transplant

Laura Benítez

Unidad de Trasplante Hepatico. HU Puerta de Hierro Majadahonda



Impact of OCS Liver Perfusion Time on Post-Transplant Survival - Real World Clinical Experience from the OCS Liver Perfusion (OLP) Post-Approval US Registry

J. F. Markmann¹, M. Hobeika², R. Ghobrial², G. Roll³, S. Syed⁴, G. Schnickel⁵, D. Sudan⁶, A. K. Mathur⁷, A. Moss⁷, M. Abouljoud⁸, OLP-Registry-Consortium⁹, ¹Mass General, Boston, MA, ²Houston Methodist Hospital, Houston, TX, ³UCSF Medical Center, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵University of California Los Angeles (Multi-Organ), San Diego, CA, ⁶Duke University Medical Center, Durham, NC, ⁷Mayo Clinic, Phoenix, AZ, ⁸Henry Ford Transplant Institute, Detroit, MI, ⁹Transmedics, Andover, MA



Background & Methods

- OLP Registry is a multi-center, observational registry collecting OCS ex-vivo perfusion & assessment parameters, as well as short and long-term post-transplant clinical outcomes of liver transplant recipients in the U.S.
- We evaluated the impact of OCS Liver perfusion time on post-transplant survival in the OLP Registry patient cohort to discern any clinical correlation.
- From Oct 2021 end Mar 2023, 799 livers were transplanted on OCS at 31 centers; data was available for analysis on 763 OCS liver cases
- 3 clinically relevant time points were analyzed:
 - Group A: ≤8 hours of OCS Liver perfusion (N=359)
 - Group B: 8-12 hours of OCS Liver perfusion (N=248)
 - Group C: >12 hours of OCS Liver perfusion (N=156)



Donor Characteristics

	Group A: <= 8hrs (N = 359)	Group B: 8-12hrs (N = 248)	Group C: > 12hrs (N =156)
Gender – n/N (%) Female Male	137/359 (38.16%) 222/359 (61.84%)	95/248 (38.31%) 153/248 (61.69%)	56/156 (35.9%) 100/156 (64.10%)
Age (years) – mean (range)	43.4 (14 – 83)	43.6 (8 – 78)	42.9 (14 – 78)
Donor Type – n/N (%) DBD DCD	201/359 (55.99%) 158/359 (44.01%)	135/248 (55.44%) 113/248 (45.56%)	58/156 (37.18%) 98/156 (62.82%)
DCD WIT (mins) – mean (range)	24.1 (10 - 106)	24.3 (8 - 74)	24.5 (13 – 93)
History of diabetes	53/359 (14.76%)	32/248 (12.90 %)	18/156 (11.54%)
History of drug use	181/359 (50.42%)	135/248 (54.44%)	71/156 (45.51%)
History of excess alcohol use	83/359 (23.12%)	59/248 (23.79%)	28/156 (17.95%)
Macrosteatosis >=40%	7/359 (1.95%)	9/248 (3.63%)	5/156 (3.21%)



Recipient Characteristics


	Group A: <= 8hrs (N = 359)	Group B: 8-12hrs (N = 248)	Group C: > 12hrs (N =156)
Gender – n/N (%) Female Male	142/359 (39.55%) 217/259 (60.45%)	76/248 (30.65%) 172/248 (69.35%)	48/156 (30.77%) 108/156 (69.23%)
Age (years) – mean (range)	55.9 (0 – 77)	56.5 (24 – 75)	56.1 (18 – 75)
MELD – mean (range)	23.6 (6 - 43)	23.1 (6 - 40)	20.4 (6 - 40)
Previous Any Organ Transplant (%)	21/359 (5.85%)	12/248 (4.84%)	5/156 (3.21%)
Previous Liver Transplant (%)	18/359 (5.01%)	10/248 (4.03%)	5/156 (3.21%)
Multiple Organ Transplant (%)	49/359 (13.65%)	35/248 (14.11%)	14/156 (8.97%)



	Group A: <= 8hrs (N = 359)	Group B: 8-12hrs (N = 248)	Group C: > 12hrs (N =156)
Donor to Recipient Hospital Distance (miles)	6.53 (0.39 – 17.86)	6.28 (0.30 – 16.55)	6.65 (0.34 – 14.84)
Recipient Location Home Hospital (floor) ICU	198/359 (55.15%) 56/359 (15.60%) 45/359 (12.53%)	149/248 (60.08%) 37/248 (14.92%) 25/248 (10.08%)	99/156 (63.46%) 14/156 (8.97%) 8/156 (5.13%)
Timing of Recipient Case (Night)	46.94%	19.14%	6.56%
Post-transplant length of stay	14.0 (3 – 114)	12.0 (3 – 154)	11.1 (3 – 63)



Patient Survival by Perfusion Group





Conclusions

- OCS Liver system perfusion times were associated with good posttransplant survival even when they extended beyond 12 hours.
- Some <u>trends</u> were evident: 1) OCS> 12h had more DCD's, fewer donor comorbidities, recipients with lower MELD, fewer from ICU, fewer night cases, shorter LOS, lower final lactate, and better survival.
- These findings have two important clinical implications:
 (1) the OCS Liver can be utilized to transport and preserve donor livers from outside the recipients' standard acceptance radius, and
 (2) the OCS Liver can be used to perfuse the donor livers overnight to better manage transplant procedure logistics.

Impact of Immune Checkpoint Inhibitors Pre-Transplantation: Intention to Treat Outcomes from a Multi-Center Study


Parissa Tabrizian, Yuki Bekki, Veeral Ajmera, Amy Kim, Kali Zhou, Gabriel Schnickel, Kelly Torosian, Maarouf Hoteit, Francis Yao, Sander Florman, Myron Schwartz, Neil Mehta




baseline characteristics (n=o

Aim

- Safety of ICI as bridge to LT
- Overall survival and recurrence (ITT and post-LT)
- Predictors of dropout from the waiting list
- Predictors of rejection post LT














Rejection post LT

Overall survival (ITT and post LT)



Conclusions

- · First multi-center ITT study on ICI in pre LT setting
- 67% DS to within MC at a median of 5.8 months
- · No grade 4-5 adverse events were reported on the wait list
- Post-LT rejection rate was 16.6% -→ predictor: ICI dose < 3 months pre LT



Minimal washout/observation period 3 months pre LT

- Encouraging pathologic response
- ITT survival at 3 years from diagnosis nearly 70%
- Clinical trials





Distinguishing an Antibody-Mediated Rejection-Like State in Liver Transplants with High Expression of NK Cell Transcripts and IFNG_Induced Transcripts



Session 15 - Liver: Immunosuppression and Rejection 22 - Distinguishing an Antibody-Mediated Rejection-Like State in Liver Transplants with High Expression of NK Cell Transcripts and IFNG-Induced Transcripts

Authors

K. S. Madill-Thomsen¹, P. T. Gauthier¹, P. F. Halloran¹, ... The INTERLIVER Study Investigators², ¹ATAGC, Edmonton, AB, Canada, ²., ., AB, Canada

Distinguishing an Antibody-Mediated Rejection-Like State in Liver Transplants with High Expression of NK Cell Transcripts and IFNG_Induced Transcripts



Background

Initial molecular analysis of liver biopsies using rejection-associated transcripts (AJT 20: 2156 2020) failed to find a DSA+ve ABMR phenotype similar to kidney transplants.

Recent kidney studies (AJT 22:1976, 2022) show that ABMR is often **DSA-ve but consistently has NK cell transcripts**.



We investigated whether a ABMR-like state exists in liver transplants, potentially missed because it is DSA-ve.

Methods




Samples assessed using genome-wide gene expression (microarrays, the Molecular Microscope® Diagnostic System).



Optimized feature selection maximized separation between TCMR and 'ABMR-like' features (validated in training/test set) and generated



4 archetype groups assigned: No-rejection (NR) N=416; TCMR N=125; ABMR-like N=98; and Recent Injury/no rejection (RI) N=126.



Distinguishing an Antibody-Mediated Rejection-Like State in Liver Transplants with High Expression of NK Cell Transcripts and IFNG_Induced Transcripts



Results (continued)



ABMR-like score top transcripts almost exclusively expressed in NK cells.



DSA status known for 157 biopsies, 76 DSA+ve. DSA was not increased in ABMR-like cases.



TCMR scores correlated strongly with T cell burden and abnormal biochemistry. ABMR-like scores correlated with NK cells but not with DSA or abnormal biochemistry.



The relatively few reported graft failures mostly followed TCMR, not ABMR-like biopsies.

CONCLUSIONS

- 1. Some liver transplants develop a clinicallysilent, ABMR-like state of unknown significance (separate from TCMR).
- 2. This state characterized by NK cell and IFNG-inducible transcripts with little parenchymal injury, similar to early-stage ABMR in kidneys but not consistently DSA+ (potential absorption by liver).
- These changes in heart & kidney transplants lead to atrophy-fibrosis - consequences in liver should be studied.



Rifaximin treatment improves liver transplant outcomes by promoting hepatocellular regeneration

Hidenobu Kojima, Shoichi Kageyama, Daisuke Noguchi, Kenneth J. Dery, <u>Taylor Torgerson</u>, Kentaro Kadono, Hirofumi Hirao, Kojiro Nakamura, Siyuan Yao, Fady M. Kaldas, Jerzy W. Kupiec-Weglinski


> The Dumont-UCLA Transplantation Center, Department of Surgery, David Geffen School of Medicine at UCLA

Aim of this study


• To clarify whether and how pre-LT rifaximin treatment affects liver transplant outcomes



Methods: animal study




Pre-transplant RFX treatment mitigated LT injury and FMT restored the liver injury



C57BL/6 to C3H




ALT





Putative mechanism



AMERICAN TRANS

JUNIO 3-7. 2023




Summary 1

- Pretransplant rifaximin treatment mitigated liver injury and enhanced liver regeneration following LT in mice.
- The effect of rifaximin was counteracted by FMT.
- 16S sequencing identified that Akkermansia muciniphila increased in two different mouse species treated by rifaximin.




Methods: retrospective study in human patients



Longer RFX treatment reduced allograft rejection

1.0 Rejection rate (%) P-value Length of rifaximine treatment (days) 3-M 6-M 1-Y 3-Y 6-M 1-Y 3-Y 5-Y 0.8 1-13 (n=56) <0.001 0.001 <0.00 <0.001 0 001 14-27 (n=46) 12 15 15 15 15 0.003 0.095 0.166 0.407 0.407 28-89 (n=40) 10 13 16 16 16 0.007 0.197 0.166 0.425 0.425 0.6 ≥ 90 (n=72) 13 13 Reference 0 6 8 0.4 0.2 0.0 270 730 1095 1460 1825 90 180 360 0 (3-M) (1-Y) (3-Y) (5-Y) (6-M) LT to 1st. rejection (days) No. at risk 56 36 33 30 17 24 13 1-13 days 17 9 34 30 29 29 24 19 17 14 46 4-27 days 32 28-90 days 40 34 28 28 25 20 16 13 67 61 60 58 42 28 72 23 19 ≥90 days

Cumulative rejection rate




Rejection rate




Methods: retrospective study in human patients

AMERICAN TRANSPLAN





Pre-transplant RFX treatment ≥ 28 days reduced incidence of early graft dysfunction (EAD)



Incidence of EAD



Summary 2

 In the clinical LT, patients with ≥ 28 d pretransplant rifaximin treatment significantly reduced EAD and improved rejection-free survival

Conclusions

- This study demonstrates the effectiveness of RFX therapy prior to LT in mice and humans.
- Akkermansia muciniphila mediated by pretransplant RFX therapy could contribute to improving LT outcomes.